FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3013776723> ?p ?o ?g. }

• W3013776723 endingPage "e000319" @default.
• W3013776723 startingPage "e000319" @default.
• W3013776723 abstract "Background Immune checkpoint inhibitors (ICIs) have expanded treatment options for metastatic renal cell carcinoma (mRCC); however, there are limited predictive biomarkers for response to ICIs in this indication, with programmed death-ligand 1 (PD-L1) status demonstrating little predictive utility in mRCC. While predictive of ICI response in other tumor types, the utility of tumor mutation burden (TMB) in mRCC is unclear. Here, we assess TMB, loss of antigen presentation genes and PD-L1 status correlated with outcomes to ICI treatment in mRCC. Methods Tumor samples from 34 patients with mRCC treated with ICI therapy at Duke Cancer Institute were retrospectively evaluated using Personal Genome Diagnostics elio tissue complete (RUO version), a tumor genomic profiling assay for somatic variants, TMB, microsatellite status and genomic status of antigen presentation genes. Tumor samples were also analyzed with the Dako 28-8 PD-L1 immunohistochemistry assay. Deidentified clinical information was extracted from the medical record, and tumor response was evaluated based on the Response Evaluation Criteria In Solid Tumors (RECIST) V.1.1 criteria. Results Patients were stratified by overall response following ICI therapy and designated as progressive disease (PD; n=18) or disease control groups (DC; n=16). TMB scores ranged from 0.36 to 12.24 mutations/Mb (mean 2.83 mutations/Mb) with no significant difference between the PD and DC groups (3.01 vs 2.63 mutations/Mb, respectively; p=0.7682). Interestingly, 33% of PD patients displayed loss of heterozygosity of major histocompatibility complex class I genes (LOH-MHC) vs 6% of DC patients. Nine of 34 samples were PD-L1-positive (4 in the PD group; 5 in the DC group), suggesting no correlation between PD-L1 expression and response to ICI therapy. Notably, the DC group displayed an enrichment of mutations in DNA repair genes (p=0.04), with 68.8% exhibiting at least one mutated homologous recombination repair (HRR)-related gene compared with only 38.9% of the PD group (p=0.03). Conclusions Overall, neither TMB nor PD-L1 correlated with ICI response and TMB was not significantly associated with PD-L1 expression. The higher incidence of LOH-MHC in PD group suggests that loss of antigen presentation may restrict response to ICIs. Separately, enrichment of HRR gene mutations in the DC group suggests potential utility in predicting ICI response and a potential therapeutic target, warranting future studies." @default.
• W3013776723 created "2020-04-03" @default.
• W3013776723 creator A5000632212 @default.
• W3013776723 creator A5003258823 @default.
• W3013776723 creator A5010848117 @default.
• W3013776723 creator A5020223699 @default.
• W3013776723 creator A5029577196 @default.
• W3013776723 creator A5033510051 @default.
• W3013776723 creator A5043593421 @default.
• W3013776723 creator A5048216930 @default.
• W3013776723 creator A5063495695 @default.
• W3013776723 creator A5080700188 @default.
• W3013776723 creator A5081806047 @default.
• W3013776723 creator A5087219811 @default.
• W3013776723 date "2020-03-01" @default.
• W3013776723 modified "2023-10-16" @default.
• W3013776723 title "Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma" @default.
• W3013776723 cites W1940241680 @default.
• W3013776723 cites W1978173977 @default.
• W3013776723 cites W2017239168 @default.
• W3013776723 cites W2028433016 @default.
• W3013776723 cites W2047958526 @default.
• W3013776723 cites W2101670384 @default.
• W3013776723 cites W2104885590 @default.
• W3013776723 cites W2115494288 @default.
• W3013776723 cites W2118527670 @default.
• W3013776723 cites W2119770043 @default.
• W3013776723 cites W2158290434 @default.
• W3013776723 cites W2170552969 @default.
• W3013776723 cites W2171992773 @default.
• W3013776723 cites W2222086386 @default.
• W3013776723 cites W2291298003 @default.
• W3013776723 cites W2335012284 @default.
• W3013776723 cites W2400328547 @default.
• W3013776723 cites W2551911481 @default.
• W3013776723 cites W2558408743 @default.
• W3013776723 cites W2627067328 @default.
• W3013776723 cites W2725858612 @default.
• W3013776723 cites W2747774814 @default.
• W3013776723 cites W2765417948 @default.
• W3013776723 cites W2774712455 @default.
• W3013776723 cites W2779221466 @default.
• W3013776723 cites W2782183686 @default.
• W3013776723 cites W2783970157 @default.
• W3013776723 cites W2792333466 @default.
• W3013776723 cites W2792937256 @default.
• W3013776723 cites W2794003569 @default.
• W3013776723 cites W2797675588 @default.
• W3013776723 cites W2801270371 @default.
• W3013776723 cites W2890909649 @default.
• W3013776723 cites W2902568381 @default.
• W3013776723 cites W2909679049 @default.
• W3013776723 cites W2910361233 @default.
• W3013776723 cites W2918549116 @default.
• W3013776723 cites W2921771466 @default.
• W3013776723 cites W2922328727 @default.
• W3013776723 cites W2924122631 @default.
• W3013776723 cites W2942836275 @default.
• W3013776723 cites W2946329325 @default.
• W3013776723 cites W2967350775 @default.
• W3013776723 cites W2971041153 @default.
• W3013776723 cites W2972162958 @default.
• W3013776723 cites W4236294751 @default.
• W3013776723 doi "https://doi.org/10.1136/jitc-2019-000319" @default.
• W3013776723 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7206964" @default.
• W3013776723 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32221016" @default.
• W3013776723 hasPublicationYear "2020" @default.
• W3013776723 type Work @default.
• W3013776723 sameAs 3013776723 @default.
• W3013776723 citedByCount "59" @default.
• W3013776723 countsByYear W30137767232020 @default.
• W3013776723 countsByYear W30137767232021 @default.
• W3013776723 countsByYear W30137767232022 @default.
• W3013776723 countsByYear W30137767232023 @default.
• W3013776723 crossrefType "journal-article" @default.
• W3013776723 hasAuthorship W3013776723A5000632212 @default.
• W3013776723 hasAuthorship W3013776723A5003258823 @default.
• W3013776723 hasAuthorship W3013776723A5010848117 @default.
• W3013776723 hasAuthorship W3013776723A5020223699 @default.
• W3013776723 hasAuthorship W3013776723A5029577196 @default.
• W3013776723 hasAuthorship W3013776723A5033510051 @default.
• W3013776723 hasAuthorship W3013776723A5043593421 @default.
• W3013776723 hasAuthorship W3013776723A5048216930 @default.
• W3013776723 hasAuthorship W3013776723A5063495695 @default.
• W3013776723 hasAuthorship W3013776723A5080700188 @default.
• W3013776723 hasAuthorship W3013776723A5081806047 @default.
• W3013776723 hasAuthorship W3013776723A5087219811 @default.
• W3013776723 hasBestOaLocation W30137767231 @default.
• W3013776723 hasConcept C104317684 @default.
• W3013776723 hasConcept C121608353 @default.
• W3013776723 hasConcept C126322002 @default.
• W3013776723 hasConcept C143589142 @default.
• W3013776723 hasConcept C143998085 @default.
• W3013776723 hasConcept C180754005 @default.
• W3013776723 hasConcept C2777472916 @default.
• W3013776723 hasConcept C2777701055 @default.
• W3013776723 hasConcept C2778822529 @default.
• W3013776723 hasConcept C2779134260 @default.

• next